Solventum (NYSE:SOLV) Hits New 12-Month High – Should You Buy?

Solventum Corporation (NYSE:SOLV) shares reached a new 52-week high during trading on Tuesday . The stock traded as high as $94.16 and last traded at $92.9160, with a volume of 60086 shares changing hands. The stock had previously closed at $91.06.

Analyst Ratings Changes

SOLV has been the subject of a number of analyst reports. UBS Group boosted their price target on Solventum from $95.00 to $101.00 and gave the stock a “buy” rating in a research report on Thursday, August 6th. Wedbush raised their price target on Solventum from $94.00 to $101.00 and gave the company an “outperform” rating in a report on Thursday, August 6th. KeyCorp raised their price target on Solventum from $93.00 to $102.00 and gave the company an “overweight” rating in a report on Thursday, August 6th. Wells Fargo & Company cut their price objective on shares of Solventum from $83.00 to $70.00 and set an “equal weight” rating on the stock in a research note on Wednesday, May 6th. Finally, BMO Capital Markets assumed coverage on shares of Solventum in a report on Wednesday, July 8th. They issued a “market perform” rating and a $81.00 price objective for the company. Eight analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $91.64.

Solventum Price Performance

The company has a fifty day simple moving average of $82.81 and a 200-day simple moving average of $75.61. The company has a market cap of $15.67 billion, a P/E ratio of 11.26, a PEG ratio of 1.17 and a beta of 0.60. The company has a debt-to-equity ratio of 1.00, a current ratio of 1.02 and a quick ratio of 0.74.

Solventum (NYSE:SOLV) last released its quarterly earnings data on Wednesday, August 5th. The company reported $2.55 earnings per share for the quarter, topping the consensus estimate of $1.91 by $0.64. The business had revenue of $2.21 billion during the quarter, compared to analyst estimates of $2.15 billion. Solventum had a return on equity of 25.09% and a net margin of 17.26%.The company’s revenue was up 2.2% compared to the same quarter last year. During the same period last year, the company posted $1.69 EPS. Solventum has set its FY 2026 guidance at 7.100-7.200 EPS. On average, sell-side analysts predict that Solventum Corporation will post 7.22 earnings per share for the current year.

Hedge Funds Weigh In On Solventum

A number of institutional investors have recently bought and sold shares of the stock. United Services Automobile Association acquired a new position in shares of Solventum in the first quarter worth about $239,000. Woodline Partners LP increased its position in shares of Solventum by 40.7% in the first quarter. Woodline Partners LP now owns 11,677 shares of the company’s stock worth $888,000 after acquiring an additional 3,377 shares in the last quarter. Intech Investment Management LLC raised its holdings in shares of Solventum by 167.0% during the first quarter. Intech Investment Management LLC now owns 16,669 shares of the company’s stock valued at $1,268,000 after acquiring an additional 10,425 shares during the period. First Trust Advisors LP raised its holdings in shares of Solventum by 5.8% during the second quarter. First Trust Advisors LP now owns 257,727 shares of the company’s stock valued at $19,546,000 after acquiring an additional 14,151 shares during the period. Finally, Marshall Wace LLP purchased a new stake in shares of Solventum in the 2nd quarter valued at approximately $766,000.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.